摘要
目的研究纤溶酶原激活物抑制剂（ＰＡＩ－１）与肝癌临床生物学特性的关系。方法用ＰＡＩ－１试剂盒检测３０例肝细胞癌（ＨＣＣ）患者血浆和肿瘤组织中ＰＡＩ－１变化，取正常人血浆和肝组织作对照。结果ＨＣＣ患者血浆和肿瘤组织中ＰＡＩ－１与对照组比明显升高，分别为１２．８±２．７５Ａｕ／ｍｌ比６．８５±２．２１Ａｕ／ｍｌ，０．８１±０．１２Ａｕ／ｍｇ比０．３８±０．１４Ａｕ／ｍｇ（Ｐ均＜０．０５）。侵袭性与非侵袭性ＨＣＣ病例比较，血浆ＰＡＩ－１为１４．９６±１．１１Ａｕ／ｍｌ比１１．４２±１．５９Ａｕ／ｍｌ（Ｐ＜０．０５）。血浆ＰＡＩ－１明显升高的ＨＣＣ患者预后较差。结论ＨＣＣ患者血浆和肿瘤组织中ＰＡＩ－１明显升高，ＰＡＩ－１与ＨＣＣ侵袭性和预后密切相关。
Objective To explore the relationship between plasminogen activator inhibitor type-1 (PAI-1)and its biological behaviour of hepatocellular carcinoma (HCC).Methods The change of PAI-1 in plasma and tumor extract of 30 patients with HCC was determined by the PAI-1 kit,normal plasma and liver tissue served as control. Results PAI-1 in plasma and tumor extract was higher in patients with HCC than that in control group,they were 12.8±2.75Au/ml vs 6.85±2.21Au/ml in plasma,and 0.81±0.12Au/mg vs 0.38 ±0.14Au/mg in tumor extract( P <0.05),respectively.PAI-1 in plasma of invasive cases and noninvasive cases were 14.96±1.11Au/ml vs 11.42±1.59Au/ml ( P <0.05),the higher the plasma PAI-1 was, the worser the prognosis. Conclusion PAI-1 was increased in plasma and tumor extract of patients with HCC,and was related to the invasiveness and prognosis of HCC.
出处
《中华消化杂志》
CAS
CSCD
北大核心
1999年第1期16-18,共3页
Chinese Journal of Digestion
关键词
肝肿瘤
肿瘤浸润
肿瘤转移
PAI-1
Plasminogen inactivators Liver neoplasms Neoplasm invasiveness Neoplasm metastasis
